Insulin-sensitising agents in polycystic-ovary syndrome

Lancet

Volumn 351, Issue 9099, 1998, Pages 305-307

  Sattar, N ^a   Hopkinson, Z E C ^a   Greer, I A ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; METFORMIN; ORAL ANTIDIABETIC AGENT; TROGLITAZONE;

ANDROGEN RELEASE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; META ANALYSIS; OVARY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0032583935     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)78345-8     Document Type: Note

References (12)

1. A Dunaif Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis Endocrine Rev 18 1997 774 800
2. A Dunaif D Scott D Finegood B Quintana R Whitcomb The insulin sensitising agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovarian syndrome J Clin Endocrinol Metab 81 1996 3299 3306
3. D Ehrmann DJ Schneider BE Sobel Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome J Clin Endocrinol Metab 82 1997 2108 2116
4. JE Nestler D Jakubowicz Decrease in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome N Engl J Med 335 1996 617 623
5. EM Velazquez SG Mendoza T Hamer F Sosa CJ Glueck Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy Metabolism 43 1994 647 654
6. EM Velazquez A Acosta SG Mendoza Menstrual cyclicity after metformin therapy in polycystic ovary syndrome Obstet Gynecol 90 1997 392 395
7. F Casimirri M Biscotti A Gambineri F Calzoni B Eliana R Pasquali Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome (abstract) Int J Obesity 21(suppl 2) 1997 S61
8. ZM Van der Spuy R Dhansay FA Nugent Adjuvant therapy with metformin to improve the therapeutic outcome in anovulatory hyperinsulinaemic women with polycystic ovary syndrome Hum Reprod 11 1996 167
9. EM Velazquez SG Mendoza P Wang CJ Glueck Metformin therapy is associated with decreased plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with polycystic ovary syndrome Metabolism 46 1997 454 457
10. O Acbay S Gundogdu Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 65 1996 946 949
11. DA Ehrmann M Cavaghan J Imperial J Sturis R Rosenfield KS Polonsky Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome J Clin Endocrinol Metab 82 1997 524 530
12. JC Crave S Fimbel H Lejeune N Cugnardey H Dechaud M Pugeat Effects of diet and metformin administration on sex hormone-binding globulin, androgens and insulin in hirsute and obese women J Clin Endocrinol Metab 80 1995 2057 2062